Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
Acumen Pharmaceuticals (NASDAQ: ABOS) has reported its financial results for 2024 and provided key business updates. The company completed enrollment in its Phase 2 ALTITUDE-AD study, investigating sabirnetug for early Alzheimer's disease, with topline results expected in late 2026.
Key financial highlights include cash position of $231.5 million as of December 31, 2024, expected to fund operations into first half of 2027. The company reported increased R&D expenses of $93.8 million (vs $42.3 million in 2023) and G&A expenses of $20.2 million (vs $18.8 million in 2023). Net loss widened to $102.3 million from $52.4 million in 2023.
Recent developments include positive Phase 1 results for a subcutaneous sabirnetug formulation and the publication of INTERCEPT-AD study results showing the drug was well-tolerated with dose-dependent target engagement.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha riportato i risultati finanziari per il 2024 e fornito aggiornamenti chiave sulle attività. L'azienda ha completato l'arruolamento nello studio ALTITUDE-AD di Fase 2, che indaga sul sabirnetug per la malattia di Alzheimer precoce, con i risultati preliminari attesi per la fine del 2026.
Tra i principali aspetti finanziari, si evidenzia una posizione di cassa di 231,5 milioni di dollari al 31 dicembre 2024, prevista per finanziare le operazioni fino alla prima metà del 2027. L'azienda ha riportato un aumento delle spese per R&S a 93,8 milioni di dollari (rispetto ai 42,3 milioni del 2023) e spese generali e amministrative di 20,2 milioni di dollari (rispetto ai 18,8 milioni del 2023). La perdita netta è aumentata a 102,3 milioni di dollari rispetto ai 52,4 milioni del 2023.
Sviluppi recenti includono risultati positivi della Fase 1 per una formulazione sottocutanea di sabirnetug e la pubblicazione dei risultati dello studio INTERCEPT-AD che mostrano che il farmaco è stato ben tollerato con un coinvolgimento del target dipendente dalla dose.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha informado sobre sus resultados financieros para 2024 y ha proporcionado actualizaciones clave sobre el negocio. La compañía completó la inscripción en su estudio ALTITUDE-AD de Fase 2, que investiga el sabirnetug para la enfermedad de Alzheimer en etapas tempranas, con resultados preliminares esperados para finales de 2026.
Los aspectos financieros clave incluyen una posición de efectivo de 231,5 millones de dólares al 31 de diciembre de 2024, que se espera financie las operaciones hasta la primera mitad de 2027. La compañía reportó un aumento en los gastos de I+D de 93,8 millones de dólares (frente a 42,3 millones en 2023) y gastos generales y administrativos de 20,2 millones de dólares (frente a 18,8 millones en 2023). La pérdida neta se amplió a 102,3 millones de dólares desde 52,4 millones en 2023.
Los desarrollos recientes incluyen resultados positivos de Fase 1 para una formulación subcutánea de sabirnetug y la publicación de los resultados del estudio INTERCEPT-AD que muestran que el fármaco fue bien tolerado con un compromiso del objetivo dependiente de la dosis.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 2024년 재무 결과를 보고하고 주요 비즈니스 업데이트를 제공했습니다. 이 회사는 조기 알츠하이머병을 위한 sabirnetug를 조사하는 2상 ALTITUDE-AD 연구에 대한 등록을 완료했으며, 주요 결과는 2026년 말에 발표될 예정입니다.
주요 재무 하이라이트에는 2024년 12월 31일 기준 2억 3,150만 달러의 현금 보유액이 포함되어 있으며, 이는 2027년 상반기까지 운영 자금을 지원할 것으로 예상됩니다. 회사는 R&D 비용이 9,380만 달러(2023년 4,230만 달러 대비 증가)로 증가했으며, 일반 및 관리 비용은 2,020만 달러(2023년 1,880만 달러 대비 증가)라고 보고했습니다. 순손실은 2023년 5,240만 달러에서 1억 230만 달러로 확대되었습니다.
최근 개발 사항으로는 피하 sabirnetug 제형에 대한 긍정적인 1상 결과와 약물이 잘 견딜 수 있으며 용량 의존적인 목표 결합을 보여주는 INTERCEPT-AD 연구 결과의 발표가 포함됩니다.
Acumen Pharmaceuticals (NASDAQ: ABOS) a publié ses résultats financiers pour 2024 et a fourni des mises à jour clés sur ses activités. La société a terminé l'inscription dans son étude ALTITUDE-AD de Phase 2, qui examine le sabirnetug pour la maladie d'Alzheimer précoce, avec des résultats préliminaires attendus pour fin 2026.
Les points financiers clés comprennent une position de trésorerie de 231,5 millions de dollars au 31 décembre 2024, prévue pour financer les opérations jusqu'au premier semestre 2027. La société a rapporté une augmentation des dépenses de R&D à 93,8 millions de dollars (contre 42,3 millions de dollars en 2023) et des dépenses générales et administratives de 20,2 millions de dollars (contre 18,8 millions de dollars en 2023). La perte nette s'est creusée à 102,3 millions de dollars contre 52,4 millions de dollars en 2023.
Les développements récents incluent des résultats positifs de Phase 1 pour une formulation sous-cutanée de sabirnetug et la publication des résultats de l'étude INTERCEPT-AD montrant que le médicament a été bien toléré avec un engagement ciblé dépendant de la dose.
Acumen Pharmaceuticals (NASDAQ: ABOS) hat seine finanziellen Ergebnisse für 2024 veröffentlicht und wichtige Geschäftsinformationen bereitgestellt. Das Unternehmen hat die Einschreibung in seine Phase-2-Studie ALTITUDE-AD abgeschlossen, die sabirnetug zur frühen Alzheimer-Krankheit untersucht, wobei die vorläufigen Ergebnisse für Ende 2026 erwartet werden.
Zu den wichtigsten finanziellen Höhepunkten gehört eine Liquiditätsposition von 231,5 Millionen Dollar zum 31. Dezember 2024, die voraussichtlich die Geschäftstätigkeit bis zur ersten Hälfte von 2027 finanzieren wird. Das Unternehmen meldete gestiegene F&E-Ausgaben von 93,8 Millionen Dollar (im Vergleich zu 42,3 Millionen Dollar im Jahr 2023) und allgemeine und Verwaltungskosten von 20,2 Millionen Dollar (im Vergleich zu 18,8 Millionen Dollar im Jahr 2023). Der Nettoverlust weitete sich auf 102,3 Millionen Dollar aus, verglichen mit 52,4 Millionen Dollar im Jahr 2023.
Zu den aktuellen Entwicklungen gehören positive Phase-1-Ergebnisse für eine subkutane Formulierung von sabirnetug und die Veröffentlichung der Ergebnisse der INTERCEPT-AD-Studie, die zeigen, dass das Medikament gut vertragen wurde und eine dosisabhängige Zielbindung aufwies.
- Strong cash position of $231.5M providing runway into H1 2027
- Early completion of Phase 2 ALTITUDE-AD enrollment with 542 participants
- Positive Phase 1 results supporting subcutaneous dosing development
- Published positive INTERCEPT-AD study results showing good tolerability
- Net loss increased significantly to $102.3M from $52.4M YoY
- R&D expenses more than doubled to $93.8M from $42.3M
- G&A expenses increased to $20.2M from $18.8M
- Phase 2 topline results not expected until late 2026
Insights
Acumen Pharmaceuticals' financial results and clinical updates reveal a mixed but generally positive picture. The company has achieved an important milestone with completed enrollment in its 540-patient Phase 2 ALTITUDE-AD study for sabirnetug in early Alzheimer's disease ahead of schedule, with topline results expected in late 2026. Additionally, topline results from a Phase 1 study of subcutaneous administration support development of this more convenient dosing option.
From a financial perspective, Acumen reported
The publication of INTERCEPT-AD Phase 1 results in JPAD showing dose-dependent target engagement and amyloid plaque reduction provides external validation of sabirnetug's mechanism. Acumen's focus on toxic amyloid beta oligomers represents a differentiated approach in the competitive Alzheimer's landscape, potentially offering improved safety and efficacy if successful in later-stage trials.
The ALTITUDE-AD enrollment completion represents a significant operational achievement in Alzheimer's drug development. With 542 early AD patients randomized across two active treatment arms (35mg/kg or 50mg/kg) and placebo, this robust sample size should provide definitive efficacy signals when results arrive in 2026.
Sabirnetug's mechanism targeting toxic soluble amyloid beta oligomers is noteworthy because it differs from approved antibodies like lecanemab and donanemab that primarily target amyloid plaques. This selectivity could potentially translate to improved safety while maintaining efficacy. The published Phase 1 INTERCEPT-AD results confirm both target engagement and downstream effects on fluid biomarkers related to Aβ, tau pathology, and synaptic dysfunction - all critical pathological hallmarks of Alzheimer's disease.
The subcutaneous formulation development is particularly important for patient convenience. Current anti-amyloid therapies require infusion center visits, creating logistical barriers to treatment. The Phase 1 data showing only mild injection site reactions (in
- Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease
- Anticipate topline results in late 2026
- Anticipate topline results in late 2026
- Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patients
- Cash, cash equivalents and marketable securities of
$231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half of 2027 - Company to host conference call and webcast today at 8:00 a.m. ET
NEWTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the full year ended December 31, 2024 and provided a business update.
“I am exceptionally proud of the considerable progress our team has made this past year in advancing the clinical development of sabirnetug, our next generation treatment for early Alzheimer’s disease. We completed enrollment in our 540-participant Phase 2 study, ALTITUDE-AD, earlier than originally anticipated and expect topline results in late 2026. We also recently announced Phase 1 topline results for a subcutaneous option of sabirnetug, that support further development of this dosing option for increased patient convenience,” said Daniel O’Connell, Chief Executive Officer of Acumen. “Looking ahead, our team remains focused on the transformative opportunity to redefine the standard of care in early Alzheimer’s disease. Through disciplined execution, continuous innovation and sabirnetug’s high selectivity for toxic amyloid beta oligomers, we believe we are well-positioned to deliver a differentiated treatment option for patients.”
Recent Highlights
- In January 2025, the Company announced that the Journal of Prevention of Alzheimer’s Disease (JPAD) published the results of its Phase 1 INTERCEPT-AD study, demonstrating that sabirnetug (ACU193) was generally well-tolerated with dose- and exposure-dependent target engagement and reduction in amyloid plaques.
- The publication titled “INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease” is available online here.
- In February 2025, JPAD also published the results of the Company’s Phase 1 INTERCEPT-AD fluid biomarker changes associated with Aβ and tau pathology and synaptic dysfunction.
- The publication titled “Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease” is available online here.
- In March 2025, the Company announced the topline results of the Phase 1 study investigating a subcutaneous (SC) administration of sabirnetug.
- The Phase 1 study in healthy volunteers enrolled 12 subjects who received single IV doses of 2,800 mg and 16 subjects who received four weekly SC doses of 1,200 mg. The most frequently reported adverse events included injection site reactions (
62.5% ), all of which were mild (Grade 1) in severity, resolved, and did not cause any discontinuations from the study. No other safety signals were identified. Importantly, SC administration of sabirnetug produced sufficient systemic exposure to enable further clinical studies of SC dosing.
- The Phase 1 study in healthy volunteers enrolled 12 subjects who received single IV doses of 2,800 mg and 16 subjects who received four weekly SC doses of 1,200 mg. The most frequently reported adverse events included injection site reactions (
- In March 2025, the Company announced the completion of patient enrollment in its Phase 2 ALTITUDE-AD study designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
- 542 individuals with early AD have been randomized to receive one of two dose levels of sabirnetug (35mg/kg or 50mg/kg once every four weeks) or placebo. The primary endpoint of the study is the change from baseline in the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months. Secondary endpoints will include the Clinical Dementia Rating – Sum of Boxes scale (CDR-SB), ADAS-Cog13, ADCS-ADL and various AD biomarkers. Standard safety measures and MRIs will also be assessed. Participants who complete the double-blind portion of the study will have the opportunity to continue into an open-label extension.
Anticipated Milestones
- The Company expects topline results from ALTITUDE-AD, a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease, in late 2026.
2024 Financial Results
- Cash Balance. As of Dec. 31, 2024, cash, cash equivalents and marketable securities totaled
$231.5 million , compared to cash, cash equivalents and marketable securities of$306.1 million as of December 31, 2023. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into the first half of 2027. - Research and Development (R&D) Expenses. R&D expenses in 2024 were
$93.8 million , compared to$42.3 million in 2023. The increase in R&D expenses was primarily due to increased costs related to clinical trial costs related to ALTITUDE-AD, personnel, license expenses and other costs. - General and Administrative (G&A) Expenses. G&A expenses in 2024 were
$20.2 million , compared to$18.8 million in 2023. The increase in G&A expenses was primarily due to increased costs related to personnel and was offset by reductions in insurance and consulting. - Loss from Operations. Loss from operations in 2024 was
$114.0 million , compared to$61.1 million in 2023. This increase was due to the increased R&D and G&A expenses over the prior year period. - Net Loss. Net loss for the year ended December 31, 2024 was
$102.3 million , compared to a net loss of$52.4 million for the year ended December 31, 2023.
Conference Call Details
Acumen will host a conference call and live audio webcast today, Mar. 27, 2025, at 8:00 a.m. ET.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.
About ALTITUDE-AD (Phase 2)
Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.
About INTERCEPT-AD (Phase 1)
Completed in 2023, INTERCEPT-AD was a Phase 1, U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and tolerability, and establishing clinical proof of mechanism, of sabirnetug in patients with early Alzheimer’s disease (AD). Sixty-five individuals with early AD (mild cognitive impairment or mild dementia due to AD) enrolled in this first-in-human study of sabirnetug. The INTERCEPT-AD study consisted of single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts. Results showed sabirnetug to be well-tolerated with a favorable overall safety profile. The trial showed amyloid plaque reduction, effects on synaptic biomarkers, low overall rates of ARIA-E, and evidence of target engagement that validated proof of mechanism. More information can be found on www.clinicaltrials.gov, NCT identifier NCT04931459.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into the first half of 2027, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, and the potential for additional development to support a subcutaneous dosing option of sabirnetug. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.
CONTACTS:
Investors:
Alex Braun
abraun@acumenpharm.com
Media: AcumenPR@westwicke.com
| Acumen Pharmaceuticals, Inc. | |||||||
| Balance Sheets | |||||||
| (in thousands, except share and per share data) | |||||||
| December 31, | |||||||
| 2024 | 2023 | ||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 35,627 | $ | 66,886 | |||
| Marketable securities, short-term | 135,930 | 176,636 | |||||
| Prepaid expenses and other current assets | 6,749 | 3,093 | |||||
| Total current assets | 178,306 | 246,615 | |||||
| Marketable securities, long-term | 59,968 | 62,553 | |||||
| Restricted cash | 232 | 233 | |||||
| Other assets, long-term | 486 | 724 | |||||
| Total assets | $ | 238,992 | $ | 310,125 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 5,648 | $ | 1,379 | |||
| Accrued clinical trial expenses | 15,344 | 4,387 | |||||
| Accrued expenses and other current liabilities | 6,615 | 6,449 | |||||
| Finance lease liability | - | 756 | |||||
| Total current liabilities | 27,607 | 12,971 | |||||
| Debt, long-term | 29,419 | 29,897 | |||||
| Other liabilities, long-term | 150 | 284 | |||||
| Total liabilities | 57,176 | 43,152 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity | |||||||
| Preferred stock, | - | - | |||||
| Common stock, | 6 | 6 | |||||
| Additional paid-in capital | 506,985 | 489,453 | |||||
| Accumulated deficit | (325,127 | ) | (222,798 | ) | |||
| Accumulated other comprehensive income (loss) | (48 | ) | 312 | ||||
| Total stockholders' equity | 181,816 | 266,973 | |||||
| Total liabilities and stockholders' equity | $ | 238,992 | $ | 310,125 | |||
| Acumen Pharmaceuticals, Inc. | |||||||
| Statements of Operations and Comprehensive Loss | |||||||
| (in thousands, except share and per share data) | |||||||
| Year Ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Operating expenses | |||||||
| Research and development | $ | 93,798 | $ | 42,318 | |||
| General and administrative | 20,219 | 18,820 | |||||
| Total operating expenses | 114,017 | 61,138 | |||||
| Loss from operations | (114,017 | ) | (61,138 | ) | |||
| Other income (expense) | |||||||
| Interest income | 14,317 | 10,791 | |||||
| Interest expense | (4,068 | ) | (581 | ) | |||
| Change in fair value of embedded derivatives | 1,590 | (1,360 | ) | ||||
| Other expense, net | (151 | ) | (83 | ) | |||
| Total other income | 11,688 | 8,767 | |||||
| Net loss | (102,329 | ) | (52,371 | ) | |||
| Other comprehensive gain (loss) | |||||||
| Unrealized gain (loss) on marketable securities | (360 | ) | 1,063 | ||||
| Comprehensive loss | $ | (102,689 | ) | $ | (51,308 | ) | |
| Net loss per common share, basic and diluted | $ | (1.71 | ) | $ | (1.08 | ) | |
| Weighted-average shares outstanding, basic and diluted | 60,013,277 | 48,609,383 | |||||
| Acumen Pharmaceuticals, Inc. | |||||||
| Statements of Cash Flows | |||||||
| (in thousands) | |||||||
| Year Ended December 31, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities | |||||||
| Net loss | $ | (102,329 | ) | $ | (52,371 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation | 63 | 61 | |||||
| Stock-based compensation expense | 9,635 | 6,145 | |||||
| Amortization of premiums and accretion of discounts on marketable securities, net | (5,015 | ) | (3,121 | ) | |||
| Change in fair value of embedded derivatives | (1,590 | ) | 1,360 | ||||
| Amortization of right-of-use asset | 115 | 123 | |||||
| Non-cash research and development expense | - | 739 | |||||
| Realized gain on marketable securities | (97 | ) | (11 | ) | |||
| Non-cash interest expense | 1,118 | 145 | |||||
| Other non-cash expense | 232 | - | |||||
| Changes in operating assets and liabilities: | |||||||
| Prepaid expenses and other current assets | (3,656 | ) | (369 | ) | |||
| Other long-term assets | 74 | (70 | ) | ||||
| Accounts payable | 4,269 | (261 | ) | ||||
| Accrued clinical trial expenses | 10,957 | 1,670 | |||||
| Accrued expenses and other liabilities | 32 | 2,879 | |||||
| Finance lease liability | (23 | ) | 17 | ||||
| Net cash used in operating activities | (86,215 | ) | (43,064 | ) | |||
| Cash flows from investing activities | |||||||
| Purchases of marketable securities | (170,731 | ) | (250,634 | ) | |||
| Proceeds from maturities and sales of marketable securities | 218,774 | 78,981 | |||||
| Proceeds from sale of property and equipment | - | 3 | |||||
| Purchases of property and equipment | (16 | ) | (21 | ) | |||
| Net cash provided by (used in) investing activities | 48,027 | (171,671 | ) | ||||
| Cash flows from financing activities | |||||||
| Proceeds from issuance of common stock, net of issuance costs | 7,938 | 121,904 | |||||
| Proceeds from Term Loan | - | 30,000 | |||||
| Payment for financing lease | (739 | ) | - | ||||
| Payments for financing costs | - | (476 | ) | ||||
| Payments for deferred offering costs | (230 | ) | - | ||||
| Repurchase of common shares to pay employee withholding taxes | (41 | ) | - | ||||
| Proceeds from exercise of stock options | - | 325 | |||||
| Net cash provided by financing activities | 6,928 | 151,753 | |||||
| Net change in cash and cash equivalents and restricted cash | (31,260 | ) | (62,982 | ) | |||
| Cash and cash equivalents and restricted cash at the beginning of the period | 67,119 | 130,101 | |||||
| Cash and cash equivalents and restricted cash at the end of the period | $ | 35,859 | $ | 67,119 | |||
FAQ
What were the key findings from Acumen's Phase 1 subcutaneous sabirnetug study in 2025?
How many participants are enrolled in ABOS's ALTITUDE-AD Phase 2 trial?
What is Acumen's (ABOS) current cash runway based on 2024 results?
What caused ABOS's increased net loss in 2024 compared to 2023?
